| Literature DB >> 2941044 |
M R Williams, K J Walker, A Turkes, R W Blamey, R I Nicholson.
Abstract
Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with a potent new luteinising hormone-releasing hormone agonist Zoladex (ICI 118630) in a phase I clinical trial. On progression of disease 26 patients have undergone therapeutic oophorectomy. We present the clinical and endocrinological responses to treatment in 45 assessable patients. The response rate to Zoladex in this series was 31% and the ER status of the primary tumour was predictive of a response to the luteinising hormone-releasing hormone.Entities:
Mesh：
Substances：
Year: 1986 PMID： 2941044 PMCID： PMC2001373 DOI： 10.1038/bjc.1986.106
Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640